Taipei, September 11th, 2023 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading pharmaceutical company, reported its unaudited consolidated revenue for August 2023. The company's revenue this month amounted to NT$1,185 million, representing 19% growth comparing to the same period last year. As of end of August, the year-to-date consolidated revenue reached NT$12,438 million, 53% higher than the first 8 months last year.
Asian markets continued to perform sustainable 16% year-over-year growth in August, driven mainly by the growth in Taiwan and SEA markets. The company also achieved a significant milestone in Japan in August. In collaboration with Fuji Pharma, Lotus’s 2.5mg and 5mg of Lenalidomide received market authorizations in Japan. This achievement is expected to further enhance Lotus's presence and performance in the Asian market.
Export businesses grew 25% this month versus the prior year. Notably, the company's softgel nintedanib 150mg, generic to Ofev®, received regulatory approval in Canada this month.
Lotus Pharmaceutical Co., Ltd. has continued its transformation from a local Taiwanese generic pharmaceutical company to a global player. Moving forward, the company remains dedicated to the development of brand, innovative, and complex products, aiming to continue realizing overall operational synergies and delivering exceptional value to its stakeholders.
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Susan Liao, IR/PR Director
+886 2 2700 5908